Alberta Precision Laboratories

Aug 22, 2024 | medrxiv.org | Deirdre Church |Thomas Griener |Dan Gregson |Alberta Precision Laboratories

The authors have declared no competing interest. This is a non-funded database study. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of University of Calgary gave ethical approval of this work under the reference number provided in the attached manuscript.

Mar 1, 2024 | onlinecjc.ca | Dennis J. Orton |Alberta Precision Laboratories |Joshua E. Raizman

Elevated lipoprotein (a) [Lp(a)] levels have been linked to atherosclerotic cardiovascular disease (ASCVD) and various cardiovascular related outcomes. In March 2021, updated Canadian Cardiovascular Society (CCS) dyslipidemia guidelines included a strong recommendation to measure Lp(a) once in a patient’s lifetime as a part of initial lipid screening.

Dec 14, 2023 | academic.oup.com | Alberta Precision Laboratories |Veldhuyzen van Zanten

Helicobacter pylori is an accepted cause of gastritis, dyspepsia, duodenal, and gastric ulcers and is a risk factor for gastric cancer. There is consensus that H. pylori-positive patients should be offered treatment. Traditionally, therapy involved “classic” triple combinations of a proton pump inhibitor (P) with clarithromycin (C) and either amoxicillin (A) (PAC) or metronidazole (M) (PMC) for 7–14 days.

Dec 14, 2023 | academic.oup.com | Alberta Precision Laboratories |Van Zanten |Sander Veldhuyzen

Helicobacter pylori is an accepted cause of gastritis, dyspepsia, duodenal, and gastric ulcers and is a risk factor for gastric cancer. There is consensus that H. pylori-positive patients should be offered treatment. Traditionally, therapy involved “classic” triple combinations of a proton pump inhibitor (P) with clarithromycin (C) and either amoxicillin (A) (PAC) or metronidazole (M) (PMC) for 7–14 days.

Nov 29, 2023 | academic.oup.com | J Dayre |Alberta Precision Laboratories

Routine influenza immunization of all pregnant individuals has been recommended in Canada since 2007 [1]; similar recommendations have been adopted by many countries since the 2009 H1N1 influenza pandemic [2]. Influenza immunization during pregnancy not only directly protects pregnant people, who are considered at high-risk for severe influenza, but also passively protects newborns through transplacental transfer of maternal anti-influenza antibodies to the fetus [3, 4].